These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 7173449

  • 1. Stimulation of non-specific resistance and specific immune response against tumours in mice by synthetic muramyl dipeptide.
    Nĕmecková S, Bubeník J, Jezek J, Zaoral M.
    Folia Biol (Praha); 1982; 28(5):327-33. PubMed ID: 7173449
    [Abstract] [Full Text] [Related]

  • 2. [Activation of the production of the tumor-necrosis factor by the combined action of lipopolysaccharide and muramyl dipeptide in vitro and in vivo].
    Fuks BB, Rakhmilevich AL, Pimenov AA, Dubrovskaia AG.
    Biull Eksp Biol Med; 1987 Oct; 104(10):497-9. PubMed ID: 3315036
    [Abstract] [Full Text] [Related]

  • 3. The test of non-specific cell-mediated response in animals with transplantable tumours stimulated with calf thymus extract.
    Jaszcz W, Chłap Z, Rzepecki W, Szot W, Piotrowska K.
    Acta Physiol Pol; 1983 Oct; 34(1):67-75. PubMed ID: 6637532
    [Abstract] [Full Text] [Related]

  • 4. [The synergistic action of lipopolysaccharide and muramyl dipeptide in the immunotherapy of DBA/2 mice with mastocytoma P815].
    Rakhmilevich AL, Rakhimova MS.
    Biull Eksp Biol Med; 1989 Dec; 108(12):721-4. PubMed ID: 2517487
    [Abstract] [Full Text] [Related]

  • 5. Opposite effects of the synthetic immunomodulator, muramyl dipeptide, on rejection of mouse skin allografts.
    Zídek Z, Capková J, Boubelík M, Masek K.
    Eur J Immunol; 1983 Oct; 13(10):859-61. PubMed ID: 6357810
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of tumor growth in mice treated with synthetic muramyl dipeptide.
    Bubeník J, Jezek J, Zaoral M, Hofmann J, Gruntenko YV, Osipov JG, Zolotareva AG, Vakhrusheva TE, Budker VG.
    Cancer Immunol Immunother; 1984 Oct; 18(2):123-5. PubMed ID: 6568871
    [Abstract] [Full Text] [Related]

  • 7. Muramyl dipeptide analogues as potentiators of the antitumor action of endotoxin.
    Bloksma N, Hofhuis FM, Willers JM.
    Cancer Immunol Immunother; 1985 Oct; 19(3):205-10. PubMed ID: 3847290
    [Abstract] [Full Text] [Related]

  • 8. Endotoxin-induced antitumor activity in the mouse is highly potentiated by muramyl dipeptide.
    Bloksma N, Hofhuis FM, Willers JM.
    Cancer Lett; 1984 Jun; 23(2):159-65. PubMed ID: 6378362
    [Abstract] [Full Text] [Related]

  • 9. Dissociation between tumour resistance and delayed-type hypersensitivity to tumour-associated antigens in the mouse.
    Henderson DC, Parker D, Turk JL.
    Immunology; 1980 Jan; 39(1):1-9. PubMed ID: 7380461
    [Abstract] [Full Text] [Related]

  • 10. Specific desensitization of resistance against a syngeneic methylcholanthrene-induced sarcoma in C3Hf mice.
    Vaage J.
    Cancer Res; 1972 Feb; 32(2):193-9. PubMed ID: 5058179
    [No Abstract] [Full Text] [Related]

  • 11. Macrophages and resistance to tumours: influence of agents affecting macrophages and delayed-type hypersensitivity on resistance to tumours inducing concomitant immunity.
    Nelson M, Nelson DS.
    Aust J Exp Biol Med Sci; 1978 Apr; 56(2):211-23. PubMed ID: 209776
    [Abstract] [Full Text] [Related]

  • 12. Modulation of anti-tumour immunity and the effect of bacterial endotoxin on the growth of different syngeneic tumours from small inocula in mice.
    Kearney R, Harrop P.
    Br J Exp Pathol; 1986 Jun; 67(3):371-81. PubMed ID: 3521708
    [Abstract] [Full Text] [Related]

  • 13. B30-MDP, a synthetic muramyl dipeptide derivative for tumour vaccination to enhance antitumour immunity and antimetastatic effect in mice.
    Yoo YC, Saiki I, Sato K, Azuma I.
    Vaccine; 1992 Jun; 10(11):792-7. PubMed ID: 1441733
    [Abstract] [Full Text] [Related]

  • 14. Castration effects on tumor-specific immunity.
    Brannen GE.
    Natl Cancer Inst Monogr; 1978 Dec; (49):101-4. PubMed ID: 748764
    [Abstract] [Full Text] [Related]

  • 15. Concomitant immunity and specific depression of immunity by residual or reinjected syngeneic tumor tissue.
    Vaage J.
    Cancer Res; 1971 Nov; 31(11):1655-62. PubMed ID: 5121668
    [No Abstract] [Full Text] [Related]

  • 16. Vascular clearance of embolic tumor cells and colloidal carbon and the levels of serum lysozyme following muramyl dipeptide administration.
    Proctor JW, Waters RV, Jones GH, Gorecka-Tisera A, Yamamura Y.
    Oncodev Biol Med; 1982 Nov; 3(2-3):179-90. PubMed ID: 7122255
    [Abstract] [Full Text] [Related]

  • 17. Concomitant immunity and specific desensitization in murine tumor hosts.
    Vaage J.
    Isr J Med Sci; 1973 Mar; 9(3):332-43. PubMed ID: 4710041
    [No Abstract] [Full Text] [Related]

  • 18. [Effect of novel derivatives of muramyl dipeptide on the immune system].
    Kaliuzhin OV, Fuks BB, Bovin NV, Zemliakov AE, Chirva VIa.
    Biull Eksp Biol Med; 1994 May; 117(5):510-3. PubMed ID: 9296705
    [No Abstract] [Full Text] [Related]

  • 19. Tumor immunity in vivo: evidence that immune destruction of tumor leaves "bystander" cells intact.
    Weissman IL.
    J Natl Cancer Inst; 1973 Aug; 51(2):443-8. PubMed ID: 4765368
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.